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ABSTRACT
The structure formula of moxifloxacin is described as follows: 8 methoxy flouroquinolone: and it is broad spectrum antibiotic [1, 2].we study moxifloxacin
by IV drug delivery system. And for its study following apparatus is used; 1-a reversed-phase Lichrospher RP-18 column, 2-a mobile phase which is composed of
different solvents.
It is detected at a wavelength of 290 nm.  By this method the retention time of moxifloxacin is very short.  When we detect it in plasma and brain tissue
linear curves are obtained. .Advantage of this method is that we can detect the bacteria in plasma and brain tissues by this method.
Keywords: Lichrospher RP-18 column, moxifloxacin, MIC.
INTRODUCTION
Most commonly founded bacteria in environment are Listeria
monocytogenes it is actually a gram-positive bacteria [3].
This bacteria is charectrized as a facultative intracellular




3- CNS infections [3].
This Listeriosis attacks the people of high risk and also
involves the immune compromised patients. [4].so we can say
that it is very effective against the functions of extracellular
and intracellular bacteria [5]
However it is noted that to detect the MIC of L.
monocytogenes strains we did not give much importance to its
origin that from where it is produced.[5] The function and
efficacy of moxifloxacin is analyzed by a model which is
named as “murine model of central listeriosis” [7], however its
drawback is that for it we needed the comprehensible study
(pharmacokinetic) of the drug in the entire body of
experimental animal. However, this is not very appropriate
way because of following reasons;
1- We obtain the false results by it like: fosfomycin is very
efficient inside the body of animal    against L.
monocytogenes but it failed to do work outside the
body [8].
2- No method 0r assay has been developed to find out
the moxifloxacin concentration in the brain and spinal
cord (CNS) and we cannot asses its toxic and effective
conc. in CNS by this method.
So there was need to search a method to find its
concentration in CNS thus, we developed a HPLC method
which is helpful in determining moxifloxacin amount in both
the; 1- Plasma, 2- CNS
Kiran Shahbaz*1,2
Shahbaz K. et al., April- May, 2016, 5(3), 2092-2098
©SRDE Group, All Rights Reserved. Int. J. Res. Dev. Pharm. L. Sci. 2093
So we assess the pharmacology of this drug by model that is
“murine model of CNS listeriosis”
PARAMETERS USED IN HPLC METHOD VALIDATION
Precision, determination range, quantization range, straight
line, accuracy, repeated reproduction, Reestablishment,
stability of sample solution and Specificity.
The accuracy is the proximity of the test results. Accuracy
should be recognized across its range.  Accuracy is assessed
by using a minimum of 9 determinations. The value which is
recommended for accuracy and precision is ±15%,
excluding for the ±20% which is lower limit of quantification
average and standard differences were calculated. Precision
is calculated by using coefficient of variation.[27]
Q.C samples were separately prepared from the calibration
standards. The sample solutions have three dissimilar
moxifloxacin quantities: close to the lower, mid and upper
LOQ straight line was obtained by scheming measurement of
curves in plasma and in copied three part different runs.
Calculation was made by different quantities of moxifloxacin
in brain tissues and plasma with sample solutions: involving
5ug/L and 250μg/L and involving 0.1 and 2.5μg/g for
brain. The curved lines were fixed by a straight line
regression system for the calibration of maximum area value
of this antibiotic in the in vivo standard solution. Drug
Moxifloxacin stability seen in analyzing replicates at three
different samples. These method are use in regards to
receipt criteria of  industrial principle to the bio investigative
validation .(26)The value which is suggested for accuracy
and precision is ±15%, except for the lower limit of
quantification for which lower limit of quantification ±20% is
up to standard. Average and standard difference were
calibrated. Precision is calculated by using coefficient of
variation (CV)[27]. Stability is tested at the initial and at the
end of the sample injection time limit of 15 h, at temp 9°C
but  beta-lactam stability was founded in patient‘s plasma at
4°C at room temperature for 12 hours.
Moxifloxacin has a broad spectrum antibacterial activity
fluoroquinolone Gram+ve bacteria Listeria monocytogenes
which is common in the atmosphere. It causes severe infections
and  facultative intracellular bacteria that is food-borne
Listeriosis[3] mostly occurs in persons with insensitive basic
diseases or having less strong immune system(4). Moxifloxacin
has fast antibacterial action not in support of in vitro and in
vivo L.monocytogenes(5). As a result moxifloxacin could be
well thought-out much competent as compared to amoxicillin,
against L. monocytogenes(6). To evaluate the specificity of
moxifloxacin in this murine(7),  pharmacokinetic study of this
fluoroquinolone was essential in plasma. Definitely, some
results can even be deceptive(8). Though, no bio analytical
testing has been done to find out moxifloxacin quantity in
brain tissues. Therefore, we promote a high-performance
liquid chromatographic technique for the purpose to find out
moxifloxacin concentration in plasma as well as in brain
tissue. Our methodology was then utilized to validate the
pharmacokinetic aspects of moxifloxacin in brain and plasma
in evaluated murine model of central nervous system(9-14).
Following the assay conditions moxifloxacin was taken from
the in vivo standard retention time was 8 minutes. The
chromatographic papers taken from the examination of two
empty matrixes reveal no invasive peaks with the same
times. Straight line curve was experiential in moxifloxacin
analysis from brain and plasma (r2 = 0.999) on the
validated quantity limits. Good results were taken for
accuracy (99.2–111.5%; 94.8–106.2%) and precision (CV
< 10%; CV < 5%) for brain tissue and plasma.
CHEMICALS:
Chemicals used here are, potassium dihydrogen phosphate,
orthophosphoric acid (85%), tetrabutylammonium bromide
(TBABr) ciprofloxacin, moxifloxacin, dipotassium hydrogen
phosphate, acetonitrile and methanol, potassium salt,
piperacillin sodium salt, Ceftazidime, ticarcillin, and
meropenem Amoxicillin, ceftriaxone, cloxacillin sodium salt,
oxacillin sodium salt, Cefotaxime sodium salt, penicillin G.
The working standard solutions, internal solutions and stock
solutions of moxifloxacin HCl and ciprofloxacin are in
methanol.
Phosphoric acid (85%) was used throughout the procedure.
Stationary phase is Atlantis T3 used for separation. Citric
buffer consisted of 25mM citric acid, 10mM sodium dodecyl
sulfate and 10mM TBABr in 500mL water and the pH was set
at 3.5 by 0.1 M NaOH.(25). The mobile phase is firstly
filtered and then gases are removed by degasser, consist of
10Mm phosphoric acid solution and pH is adjusted at 2 with
hydrochloric acid and acetonitrile. A linear gradient from 7%
to 19% acetonitrile in 6 min and 19% to 49% from 6 to 16
min was used by means of a flow rate of 2 ml/min. Run time
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was delayed to 22 min to go back early point. It was
monitored at 210 nm for cloxacillin, at 230 nm for
amoxicillin, at 298nm for imipenem and meropenem then the
data is recorded. The Quantification was based on the peak
heights. The baseline is inspected and adjusted visually and
also manually.
INSTRUMENTATION
Chromatographic analysis was executed on a HPLC system
that consists a fluorescence detector, a pump, degasser and
a thermostat (at 25C) 717 plus auto sampler waters.
Separation was performed by the use of a reversed-phase
Lichrospher C18 column (250 × 4 mm, 5μm). The mobile
phase consisted of mixture of acetonitrile-methanol-buffer
(pH 3.5) (40 : 3 : 57, v/v/v) at a flow rate of 1.0mL/min All
the data was evaluated by using Chrome eon.. Fluorescence
findings were performed at an emission wavelength that is
550 nm and an excitation wavelength that is 290 nm.
SAMPLE PREPARATION
In case of moxifloxacin 100μL of plasma is taken and then
add working standard internal solution 20μL for brain (in 0.5
milliliters of water 0.5g crumpled).Then tasters were
deproteinized with the help of 100μL acetonitrile. Then for
10 minutes at 3000rpm centrifuge the samples. 400µL of
sterile water was adding in 100µL supernatant. Then 20µL
of this solution is injected into system of HPLC. We mixed the
ciprofloxacin soln.20μL to 100μL for brain. Then, repeat the
above injecting technique for plasma samples.
For beta-lactam antibiotics prepare stock solution and
stockpiled at -80 °C. To prepare standard solution of
10μg/ml, mixed with water to acquire a 1-mg/ml. Three
operational solution of beta-lactam were prepared from
stock solution and diluted 10-folds in complete plasma.



















20 22.3 ± 0.3 1.5 111.5 19.9 ± 1.9 9.5 99.0
125 125.5 ± 1.3 1.0 100.4 125.6 ± 2.8 2.2 100.5





















0.2 0.19 ± 0.01 3.6 94.8 0.21 ± 0.01 5.0 105.5
1.25 1.33 ± 0.03 2.5 106.2 1.30 ± 0.04 3.0 104.3
2.25 2.17 ± 0.03 1.4 96.6 2.26 ± 0.11 5.0 100.4
Shahbaz K. et al., April- May, 2016, 5(3), 2092-2098
©SRDE Group, All Rights Reserved. Int. J. Res. Dev. Pharm. L. Sci. 2095
Then take plasma in heparin zed tubes and transported to
ice and centrifuge for 10 mints at4°C.700μl and 20μl of
water added to 100μl patient plasma sample. Each sample
was assorted and centrifuged. 900μl of water is used to
dilute 100 μL of the supernatant. 20μl were inoculated into
the system. These dilutions provide the same percentage of
acetonitrile as early condition of linear gradient.
EXPERIMENTAL MODELS
7-8 weeks old female mice were used. The bacteriologist in
laboratory used to stimulate listeriosis in 3 mice.The mice had
weighed 23-27gm and afterward injected intravenously by
means of the tangential in the vein of tail 105L× 1. An
intraperitoneal injection of drug (50mg/kg) was injected in
the mice, at 36 hours after infection.
PHARMACOKINETIC ANALYSIS:
In the mouse plasma and brain the pharmacokinetic profiles
were examine after administering a single dose of
moxifloxacin. They were deliberated from specimens
collected at zero, five, fifteen, thirty, sixty, 120, 240, 360,
and 480 minutes after 1st dose. Six mice from every group
were slater on every sampling time. Concentration time data
were examined using a non-compartmental model with first-
order elimination and zero-order absorption through a
nonlinear least squares method.
Pharmacokinetic limitations were anticipated via consistent
techniques. After directly review of investigational
concentrations time curves highest brain and plasma
concentrations (Cmax) were determined. We determined the
AUC via Trapezoidal rule until determine the variation of last
pharmacokinetic parameter between control and infected
mice. Results are stated as means ± S.D. The procedures
defined above were employed in the determination of mean
moxi concentrations. In plasma, for diseased mice, the moxi
Cmax for controlled and infected group 6.7±1.2 mg/L,
17.3±6.6 mg/L respectively.
After intraperitonial administration of moxifloxacin
concentration in brain tissues was quickly perceived within 5
min and peaked point at 1.8- 2.2μg/g as compared with
0.5-1.1μg/g in the control group within 60 minutes.
We used HPLC technique to measure moxi diffusion in blood
and cerebral tissues. Ba et al. was performed optimization of
the method by the modification of numerous pre-analytical
and investigative stages (9). Mice blood and cerebral tissues
testers were treated by deproteinization due to its low
protein binding. We decided, confirm the method using
ciprofloxacin as an internal standard owing to the extraction
efficiency (1).
Parting was accomplished by ion-pairing reversed-phase
chromatography with 10 milimole strength of SDS (12). Liang
exposed that over this strength, resolution of fluoroquinolone
was not upgraded and column equilibrium time was ideal.
TBABr was mixed at the strength of 10mM to rise resolution
between moxi and cipro, and to increase the peak nature
(9,12). The pH of the mobile phase was fixed at 3.5 with citric
acid buffer solution at strength of 25mM. Lastly, the adjusted
mobile phase comprised of 10mM TBABr, 10mM SDS, 3%
methanol, 25mM citric acid, 40 percent acetonitrileat
3.5pH.Moxi and cipro have more sensitivity and specificity
for flouresence detection than ultra voilet detection that’s
why it is used.
For determining moxifloxacin dual matrix the HPLC method
was used. The lower LOQ was 0.1 g/L & 5g/L in brain and
plasma respectively (11;15). The HPLC procedure is very
helpful and necessary for determining the cerebral
penetration as well as pharmacokinetics of the moxifloxacin.
For moxifloxacin quantification in body fluids, many methods
were illustrated (12; 13; 17). After administration of moxifloxacin
in peritoneal cavity its cerebral penetration was determined.
Rodriguez-Cerrato induced E. coli meningitis in rabbits and
then determined penetration of moxifloxacin in CSF (13).
Pharmacokinetic study of moxifloxacin on non-inflamed
meninges was done by Kanellakopoulou (10; 13). Moxifloxacin
was administered by Wise et al. in control and infected mice
and was detected in brain after 6 and 8 hours respectively
(7; 18). Twelve beta lactam antibiotics were separated at
wavelength 210, 230, and 298 nm. Mobile phase absorbed
UV which results in variation from baseline. Another method
was used in which polar drugs were retained and non-polar
drugs were eluted. Mobile phase pH also effect the retention
time. Drugs were well separated at acidic pH.  Increase in
pH decreases the retention time. These compounds were
separated in 22 min. Imipenem shows the phenomenon of
tautomerism due to which 2 peaks were obtained which were
not resolved even on making dilutions with buffer of different
pH (31; 28). 1st peak is considered as plasma concentration
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peak. When a graph is plotted between retention time and
mobile phase pH, linear line of cefepime, ceftazidime,
amoxicillin, cefotaxime, meropenem and imipenem is
obtained at concentration of 2-250 g/ml and of penicillin G,
aoxacillin, piperacillin, cloxacillin and ceftriaxone at
concentration of 5-250 g/ml.
CONCLUSION:
We authorized and developed HPLC method for
moxifloxacin in brain and plasma and its entrance in CNS
was verified. We recommended that any infection may alter
the pharmacokinetic data of the moxifloxacin as expected.
Penetration of drug in the infectious tissue is much more than















Infec. .75 11.7-23.9 1.9 .02 3.5 27.1







Infec. .75 1.8- 2.2 21.7 3.3
Cont. One 0.5 – 1.1 10.7 1
Figure: Compartive retention time of different antibiotics
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healthy tissue when the concentration of drug is increased.
This method can also be used for quantification of drug in
other body organs and diseases. It is a quick method and
used for quantification of antibiotics in plasma in daily life
(21; 32). e.g use for TDM. (29; 33).
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